Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...

Adagene (ADAG) announced data at the SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. The two poster presentations ...

About Mural Oncology's IL-12 Program Native IL-12 is a highly potent pro-inflammatory cytokine, but because of its very ...

When resistance to or failure of hypomethylating agents (HMAs) occurs in acute myeloid leukemia (AML), depleting a ligase ...

While Monday’s trading session was a win for CERo shareholders, the stock’s year-to-date (YTD) performance paints a more complex picture. As of today, CERO is down by a staggering -98.59% YTD, which ...

Drugs that have a narrow therapeutic index, such as tacrolimus, cyclosporine, or again, cyclophosphamide, might also be amenable to TDM, he said. “The two main reasons why somebody would go on ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior year period. The increase in research and development expense was primarily ...

BRTX-100, a novel cell-based therapeutic engineered to target areas of the body ... ("VAS”) and at least a 30% increase in ...

Researchers map the unique genetic regulation of proteins in human cerebrospinal fluid, identifying potential targets for ...

He and his colleagues assessed outcomes out to 10 years in 404 patients (mean age, 45 years; 76% women; mean body mass index, 37.3) who underwent ESG ... with the Center for Advanced Therapeutic ...

The Croatian health care strike is set for Monday. Despite this, emergency and urgent medical situations will still be dealt ...